Inotek snags $21M for PhII glaucoma drops

Lexington, MA's Inotek Pharmaceuticals has pulled down a $21 million round to advance its lead product, designed to ease in-eye pressure for glaucoma patients. Inotek's eye drop, dubbed trabodenoson, works in tandem with glaucoma therapy latanoprost to increase fluid outflow in the eye's trabecular meshwork, and the cash will carry Inotek through a Phase II study of the duo, the company said. More

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.